- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Study: 'All Men with PSAs Between 3 and 20 ng/mL Should Undergo MRI Before Biopsy'
In a study of over 23,000 men who had PSA testing, researchers found that the adoption of pre-biopsy MRI resulted in a 21 percent decrease in negative biopsies and a 37 percent increase in the proportion of diagnosed Gleason score 7 to 10 prostate cancers.
Can pre-biopsy magnetic resonance imaging (MRI) have an impact in reducing unnecessary biopsies?
In a new retrospective study, recently published in JAMA Network Open, researchers in Sweden compared a 2.4-year time period when pre-biopsy MRI use was low (from November 2, 2015 to February 28, 2018) and a subsequent 2.4-year time period (from March 1, 2018 to July 31, 2020) that showed a gradual increase of pre-biopsy MRI use in patients with suspected prostate cancer. The cohort was comprised of 23,802 men (mean age of 60.8) who had prostate-specific antigen (PSA) testing, according to the study. The researchers pointed out that pre-biopsy MRI has been recommended in national prostate cancer guidelines in Sweden since 2018.
The researchers found the use of pre-biopsy MRI was associated with a 7 percent rate of negative biopsies in comparison to 28 percent prior to adoption of pre-biopsy MRI. Diagnosis of Gleason score 6 cancers declined by 18 percent (6 percent vs. 24 percent) during the pre-biopsy MRI period of the study, according to the study authors.
The study authors also found that use of pre-biopsy MRI also resulted in a 37 percent increase in the proportion of diagnosed Gleason score 7 to 10 cancers (86 percent vs. 49 percent) in comparison to the period prior to wider use of pre-biopsy MRI.
“In this population-based cohort study, the introduction of MRI was associated with a decrease in prostate biopsies, a decrease in negative biopsies, and a decrease in the detection of Gleason score 6 cancer, whereas the detection of Gleason score 7 or higher cancer increased,” wrote lead study author David Robinson, Ph.D., who is affiliated with the Department of Urology at Highland Hospital in Eksjo, Sweden, and colleagues.
For men diagnosed with prostate cancer who had an initial PSA of 3 < 20 ng/mL, the researchers added that a sensitivity analysis revealed a 22 percent reduction in Gleason score 6 cancers detected via pre-biopsy MRI (16 percent vs. 38 percent). Multivariable regression modelling revealed that higher use of pre-biopsy MRI led to fewer biopsies and a decreased risk of negative biopsies (odd ratio of 0.70) in comparison to the period prior to wider use of pre-biopsy MRI.
While emphasizing the need for larger cohort studies to validate these findings and explore the impact of pre-biopsy MRI on pertinent subgroup populations, Robinson and colleagues said the current findings “support that all men with PSAs between 3 and 20 ng/mL should undergo MRI before biopsy.”
In regard to study limitations, the researchers noted that the peak of the COVID-19 pandemic occurred during the study period with a corresponding decrease in PSA testing. They also noted a lack of clear separation between targeted and systematic biopsies reported in Sweden’s National Prostate Cancer Register (NPCR).
Study Shows MRI-Targeted Biopsies Reduce Overdiagnosis of Clinically Insignificant PCa by 57 Percent
September 27th 2024Omitting biopsy procedures in men with PSA levels > 3 ng/ml and negative MRI findings for prostate cancer (PCa) was associated with significantly lower risks of diagnosing clinically insignificant PCa in comparison to the use of systematic biopsy, according to an approximately four-year study of over 13,000 men who had prostate cancer screening.
PSMA PET/CT or mpMRI: Which is Better for Diagnosing Biochemical Recurrence of PCa?
September 24th 2024A new meta-analysis found that PSMA PET/CT offers a 12 percent higher positivity rate for detecting biochemical recurrence of PCa and a 19 percent higher positivity rate for identifying lymph node metastasis in comparison to mpMRI.
Emerging PSMA Radioligand Therapy Shows Benefits for Metastatic Castration-Resistant Prostate Cancer
September 16th 2024The PSMA-targeted modality 177Lu-PNT2002 improved radiographic progression-free survival by 29 percent in patients with mCRPC in comparison to ARPI therapy, according to new phase 3 trial data presented at the ESMO Congress in Spain.
